csg-admin-2019

August 5, 2021

Aardvark Therapeutics, Inc., Completes $29M Series B Funding Led by Sorrento Therapeutics and Including Existing Investors and The Foundation for Prader-Willi Research

Funds will support three Phase 2 clinical trials of Aardvark’s lead compound to be initiated this year and advance additional products in the pipeline San […]

July 16, 2021

Richard Gabriel, B.S., M.B.A., Life Sciences Entrepreneur, Joins CSG Advisory Board; Deirdre Y. Gillespie, M.D., Steps Down After 15 Years

Adds deep experience in life sciences company creation and development including M&A. Brings expertise in chemical manufacturing including GMP and FDA regulatory compliance and submissions. […]

July 1, 2021

Exacis Biotherapeutics Makes Strategic Investment in Manufacturing by Hiring Head of Technical Operations and Securing Space in a GMP Cleanroom Facility Recently Completed by Factor Bioscience

Exacis Biotherapeutics Bryan Jones PhD brings significant experience to role of Head of Technical Operations Cleanroom facility gives Exacis capacity to produce mRNA-based cell therapies […]

March 26, 2021

Exacis Biotherapeutics Develops mRNA-Engineered iPSC-Derived NK Cells for Difficult-To-Treat Tumors

Exacis Biotherapeutics Exacis has generated NK cells from iPSCs engineered using mRNA gene-editing technology to resist rejection by the patient’s immune system ExaNK™ cells show […]